Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 182

Similar articles for PubMed (Select 23338540)

1.

Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

Deeks ED.

Drugs. 2013 Jan;73(1):75-97. doi: 10.1007/s40265-013-0009-3. Review.

PMID:
23338540
2.

Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.

Punzi L, Lapadula G, Mathieu A.

BioDrugs. 2014 Apr;28 Suppl 1:S25-37. doi: 10.1007/s40259-013-0065-y. Review.

PMID:
24687236
3.

Certolizumab pegol: in rheumatoid arthritis.

Duggan ST, Keam SJ.

BioDrugs. 2009;23(6):407-17. doi: 10.2165/11202800-000000000-00000. Review.

PMID:
19894782
4.

Certolizumab pegol for the management of Crohn's disease in adults.

Rivkin A.

Clin Ther. 2009 Jun;31(6):1158-76. doi: 10.1016/j.clinthera.2009.06.015. Review.

PMID:
19695385
5.

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.

Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D.

Ann Rheum Dis. 2009 Jun;68(6):797-804. doi: 10.1136/ard.2008.101659. Epub 2008 Nov 17.

6.

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.

Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V.

Ann Rheum Dis. 2009 Jun;68(6):805-11. doi: 10.1136/ard.2008.099291. Epub 2008 Nov 17.

7.

Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.

Dhillon S.

Drugs. 2014 Jun;74(9):999-1016. doi: 10.1007/s40265-014-0239-z. Review.

PMID:
24919863
8.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Gálvez Muñoz JG, Saiz Cuenca ES, Fry-Smith A.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD007649. doi: 10.1002/14651858.CD007649.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;9:CD007649.

PMID:
21328299
9.

Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.

Smith LS, Nelson M, Dolder CR.

Ann Pharmacother. 2010 Feb;44(2):333-42. doi: 10.1345/aph.1M314. Epub 2010 Jan 5. Review.

PMID:
20118143
10.

Maintenance therapy with certolizumab pegol for Crohn's disease.

Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators.

N Engl J Med. 2007 Jul 19;357(3):239-50. Erratum in: N Engl J Med. 2007 Sep 27;357(13):1357.

11.
12.

Certolizumab pegol in rheumatoid arthritis: current update.

Fechtenbaum M, Md Yusof MY, Emery P.

Expert Opin Biol Ther. 2014 Jun;14(6):841-50. doi: 10.1517/14712598.2014.900043. Epub 2014 Mar 22. Review.

PMID:
24654999
13.

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.

Connock M, Tubeuf S, Malottki K, Uthman A, Round J, Bayliss S, Meads C, Moore D.

Health Technol Assess. 2010 Oct;14(Suppl. 2):1-10. doi: 10.3310/hta14suppl2/01. Review.

14.

Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety.

Mease PJ.

Rheumatology (Oxford). 2011 Feb;50(2):261-70. doi: 10.1093/rheumatology/keq285. Epub 2010 Sep 25. Review.

15.

Certolizumab for rheumatoid arthritis.

Markatseli TE, Papagoras C, Nikoli A, Voulgari PV, Drosos AA.

Clin Exp Rheumatol. 2014 May-Jun;32(3):415-23. Epub 2014 Jan 20. Review.

PMID:
24447441
16.

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.

Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P, Shaughnessy L, VanLunen B, van der Heijde D.

Ann Rheum Dis. 2014 Dec;73(12):2094-100. doi: 10.1136/annrheumdis-2013-203695. Epub 2013 Aug 5.

17.

Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.

Pasut G.

BioDrugs. 2014 Apr;28 Suppl 1:S15-23. doi: 10.1007/s40259-013-0064-z. Review.

PMID:
24687235
18.

RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.

Ramiro S, van Tubergen AM, Landewé RB.

Expert Rev Clin Immunol. 2010 Sep;6(5):713-20. doi: 10.1586/eci.10.67. Review.

PMID:
20828279
19.

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Keystone E, Heijde Dv, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K.

Arthritis Rheum. 2008 Nov;58(11):3319-29. doi: 10.1002/art.23964. Erratum in: Arthritis Rheum. 2009 May;60(5):1249.

20.

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.

Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ.

Aliment Pharmacol Ther. 2011 Mar;33(5):541-50. doi: 10.1111/j.1365-2036.2010.04568.x. Epub 2011 Jan 12.

PMID:
21223344
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk